Login
Zynerba Pharmaceuticals NASDAQ: ZYNE
Zynerba’s mission is to develop next-generation transdermally-delivered cannabinoid therapeutics to help address significant unmet medical needs and improve the lives of patients with rare and near-rare neuropsychiatric conditions
| Name | Zynerba Pharmaceuticals |
| Ticker | ZYNE |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Cannabinoid Therapeutics |
| Price | 3.58 |
| 52W Low/High | 2.90 / 6.54 |
| Market cap | 105 M |
| 1Y Total Return |
-33.46%
Weak |
| 1Y Volatility |
97.74%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Zynerba’s mission is to develop next-generation transdermally-delivered cannabinoid therapeutics to help address significant unmet medical needs and improve the lives of patients with rare and near-rare neuropsychiatric conditions
Details
| Ticker | ZYNE |
| Name | Zynerba Pharmaceuticals |
| ISIN | US98986X1090 |
| CUSIP | 98986X109 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Cannabinoid Therapeutics |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 1/22/21
| Close Price | 3.58 |
| 52W Low/High | 2.90 / 6.54 |
| Market cap | 105 M |
| 1Y Total Return |
-33.46%
Weak |
| 1Y Volatility |
97.74%
High Risk |
| Beta | 2.80 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | - |
| Cash from Op. / Cur. Liabilities | -3.96 |
| Diluted Earnings / Share | -2.09 |
| ROE | - |
| ROIC | -1,070.7% |
| Price / Revenue | - |
| Price / Book | 1.6 |
| Price / CF | -2.5 |
| Current Ratio | 7.1 |
| Cur.Liabilities / Tot.Liabilities | 1.0 |
| Financial Leverage | 0.00 |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Gross Profit |
-
|
0
|
-
|
-
|
0
|
0
|
|
| R&D |
37
|
18
|
28
|
22
|
15
|
5
|
|
| EBITDA |
-52
|
-30
|
-40
|
-31
|
-22
|
-9
|
|
| Operating Income |
-53
|
-31
|
-41
|
-31
|
-22
|
-9
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
29
|
23
|
17
|
13
|
9
|
6
|
|
| EPS exc. Extra |
-2.09
|
-1.45
|
-2.88
|
-2.59
|
-2.31
|
-3.06
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
77
|
94
|
73
|
73
|
36
|
47
|
|
| Cash, Eq & Invt ShortTerm |
64
|
78
|
66
|
66
|
32
|
45
|
|
| Total Current Assets |
75
|
94
|
73
|
73
|
36
|
47
|
|
| Total Non-Current Assets |
2
|
0
|
0
|
0
|
1
|
0
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
11
|
9
|
9
|
8
|
5
|
3
|
|
| Total Current Liabilities |
11
|
9
|
9
|
8
|
5
|
3
|
|
| Long Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Shareholder equity |
67
|
85
|
64
|
65
|
31
|
44
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-42
|
-34
|
-33
|
-25
|
-18
|
-8
|
|
| Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash from Investing |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Capex |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash from Financing |
29
|
45
|
33
|
59
|
5
|
49
|
|
| Stock Issued |
30
|
47
|
33
|
59
|
5
|
42
|
|
| Debt (LT) Issued |
-1
|
-2
|
0
|
0
|
0
|
0
|
|
| Free Cash Flow |
-51
|
-30
|
-40
|
-27
|
-20
|
-
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
7.1
|
10.1
|
8.0
|
8.6
|
7.2
|
17.3
|
|
| Financial Leverage D/E |
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
|
| Return on Capital Avg |
-1,070.7%
|
-1,181.5%
|
-
|
-
|
-
|
-
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available